Battling obesity? Forget the quick fix, because medical experts are saying it's a lifelong journey, not a one-time cure. The Taiwan Medical Association for the Study of Obesity has just released its 2025 Clinical Practice Guidelines on Adult Obesity, and the message is clear: managing obesity requires comprehensive, ongoing care. This isn't about popping a pill and magically transforming; it's about a multifaceted approach.
The announcement was made at the association's 25th annual congress, alongside the 9th Japan-Korea-Taiwan Symposium on Obesity, held at National Taiwan University Hospital.
These new guidelines echo the World Health Organization (WHO)'s latest stance, including its recent global guidelines on using glucagon-like peptide-1 (GLP-1) therapies. The WHO recognizes obesity as a chronic, relapsing disease.
Association president Lin Wen-yuan highlighted that the WHO's new guidelines emphasize that obesity is a chronic disease treatable with comprehensive, lifelong care. The guidelines also acknowledge that GLP-1 therapies can be used long-term for adults. However, medication alone isn't the solution.
The WHO's definition of obesity goes beyond just weight; it's a complex interplay of genetics, neurobiology, eating habits, access to healthy food, market forces, and the broader environment.
So, what's the plan? GLP-1 therapies can be a tool, but only as part of a larger strategy. This includes a healthy diet, regular exercise, and support from healthcare professionals.
The 2025 guidelines offer a more nuanced approach to diagnosis. They look beyond just Body Mass Index (BMI), also considering waist circumference, body composition, and metabolic risks. This allows for a more personalized assessment.
But here's where it gets controversial... The guidelines outline a range of treatment options: lifestyle adjustments, nutrition plans, physical activity, mental support, medications (including GLP-1 therapies), endoscopic bariatric therapy, and even bariatric surgery. Plus, they offer tailored recommendations for specific groups, like the elderly, pregnant women, and those going through menopause.
Patient-centered care is key, with an emphasis on empathetic communication and avoiding stigmatization.
Now, let's talk numbers. The WHO defines obesity as a BMI of 30 or higher for adults, while Taiwan's guidelines consider a BMI of 27 or higher as the threshold.
Secretary-general Kao Hsiang-han explained that people with a BMI of 27 or higher, and at least one related health issue, are eligible for GLP-1 therapy. Those with a BMI between 24 and 27 are considered overweight and are advised to try lifestyle changes first.
And this is the part most people miss... Lin also pointed out the potential for misuse of GLP-1 therapies, such as use by people who are not obese or excessive use. This can lead to health risks, including significant muscle loss. Therefore, these therapies should only be prescribed and monitored by healthcare professionals.
What do you think? Are you surprised by the emphasis on long-term care? Do you think the guidelines strike the right balance between medication and lifestyle changes? Share your thoughts in the comments!
